Q1 EPS Estimates for Stoke Therapeutics Raised by Wedbush

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Investment analysts at Wedbush boosted their Q1 2025 EPS estimates for shares of Stoke Therapeutics in a research report issued to clients and investors on Tuesday, January 7th. Wedbush analyst L. Chico now anticipates that the company will post earnings of ($0.56) per share for the quarter, up from their prior forecast of ($0.59). The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.03) per share. Wedbush also issued estimates for Stoke Therapeutics’ Q2 2025 earnings at ($0.49) EPS, Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($2.08) EPS, FY2026 earnings at ($2.32) EPS, FY2027 earnings at ($2.53) EPS and FY2028 earnings at ($2.27) EPS.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.05. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The firm had revenue of $4.89 million during the quarter, compared to analyst estimates of $3.46 million.

STOK has been the subject of several other reports. HC Wainwright restated a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Leerink Partners began coverage on Stoke Therapeutics in a research note on Monday, October 14th. They issued an “outperform” rating and a $18.00 price objective for the company. Chardan Capital started coverage on shares of Stoke Therapeutics in a research report on Friday, December 20th. They set a “buy” rating and a $24.00 price objective for the company. Finally, Leerink Partnrs upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $21.29.

Stoke Therapeutics Trading Up 0.4 %

NASDAQ:STOK opened at $9.00 on Friday. The stock has a 50 day moving average of $11.91 and a two-hundred day moving average of $13.04. The firm has a market cap of $476.70 million, a P/E ratio of -4.29 and a beta of 0.95. Stoke Therapeutics has a 12 month low of $4.09 and a 12 month high of $17.58.

Institutional Investors Weigh In On Stoke Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp raised its holdings in shares of Stoke Therapeutics by 28.9% during the second quarter. Bank of New York Mellon Corp now owns 115,892 shares of the company’s stock worth $1,566,000 after acquiring an additional 25,988 shares in the last quarter. Rhumbline Advisers boosted its holdings in Stoke Therapeutics by 14.3% in the second quarter. Rhumbline Advisers now owns 47,860 shares of the company’s stock worth $647,000 after purchasing an additional 5,990 shares in the last quarter. Los Angeles Capital Management LLC increased its position in Stoke Therapeutics by 7.2% during the second quarter. Los Angeles Capital Management LLC now owns 66,765 shares of the company’s stock worth $902,000 after buying an additional 4,508 shares during the last quarter. Quest Partners LLC bought a new position in Stoke Therapeutics during the second quarter valued at about $29,000. Finally, American Century Companies Inc. lifted its position in shares of Stoke Therapeutics by 99.4% in the second quarter. American Century Companies Inc. now owns 59,149 shares of the company’s stock worth $799,000 after buying an additional 29,489 shares during the last quarter.

Insider Transactions at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 13,945 shares of the company’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $12.78, for a total value of $178,217.10. Following the transaction, the insider now owns 47,332 shares of the company’s stock, valued at approximately $604,902.96. This represents a 22.76 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel Jonathan Allan sold 13,666 shares of the company’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $13.61, for a total transaction of $185,994.26. Following the sale, the general counsel now directly owns 21,476 shares of the company’s stock, valued at $292,288.36. This represents a 38.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 62,849 shares of company stock worth $809,421. 11.30% of the stock is currently owned by company insiders.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.